GLIFLOEAST V

GLIFLOEAST V is a unique combination of Dapagliflozin and Vildagliptin , Dapagliflozin is an SGLT2 inhibitor used to manage type 2 diabetes by promoting glucose excretion through urine, thereby lowering blood sugar levels. It also offers benefits for heart failure and chronic kidney disease by reducing cardiovascular risk and improving kidney function.

Vildagliptin is a DPP-4 inhibitor that enhances insulin secretion and reduces glucagon levels, helping to regulate blood sugar in type 2 diabetes patients. It is often used in combination with other antidiabetic medications for better glycemic control.